This was realized by inhibiting NF-κB/NLRP3 signaling pathway (Deng et al., 2022); in addition, both in vitro and in vivo experiments discovered that kinsenoside could inhibit the radiation-induced liver fibrosis by regulating CTGF and TGF-β1/Smad/CTGF pathway; moreover, kinsenoside exhibited negligible adverse effects during tumor radiotherapy. The gene discussed is CCN2; the disease is neoplasm.